stockrowCelcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
Follow CELC
Alert me
Celcuity, Inc. (CELC) Return on equity
Celcuity, Inc.'s return on equity over the twelve months to 30 June 2026 was −1,433.7%, down 1269.9 percentage points from fiscal 2025 (−163.8%). Over the past ten years it has ranged from −163.8% (fiscal 2025) to −26.4% (fiscal 2018) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −163.8% | (76.26) |
| FY2024 | −87.5% | (40.91) |
| FY2023 | −46.6% | (6.75) |
| FY2022 | −39.9% | 33.75 |
| FY2021 | −73.6% | (12.51) |
| FY2020 | −61.1% | (28.15) |
| FY2019 | −33.0% | (6.60) |
| FY2018 | −26.4% | 7.42 |
| FY2017 | −33.8% | 28.51 |
| FY2016 | −62.3% | (19.74) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.3% |
| DNLI Denali Therapeutics Inc. compare | −33.9% |
| IDYA IDEAYA Biosciences, Inc. compare | −38.5% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −319.8% |
| CELC Celcuity, Inc. | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)